moxonidine has been researched along with cardiovascular agents in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blue, DR; Dillon, MP; Eglen, RM; Jasper, JR; Lesnick, JD; MacLennan, SJ; Zhu, QM | 1 |
| Poole-Wilson, PA; van Veldhuisen, DJ | 1 |
1 review(s) available for moxonidine and cardiovascular agents
| Article | Year |
|---|---|
The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure.
Topics: Bosentan; Cardiovascular Agents; Deoxyepinephrine; Heart Failure; Humans; Imidazoles; Mibefradil; Pyrazines; Quinolines; Sulfonamides; Xamoterol | 2001 |
1 other study(ies) available for moxonidine and cardiovascular agents
| Article | Year |
|---|---|
Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice.
Topics: Adrenergic alpha-Antagonists; Amino Acid Substitution; Animals; Binding, Competitive; Blood Pressure; Cardiovascular Agents; Cell Line; Clonidine; Consciousness; Dogs; Heart Rate; Humans; Imidazoles; In Vitro Techniques; Isoquinolines; Male; Mice; Mice, Inbred Strains; Mice, Transgenic; Mutation; Naphthyridines; Oxazoles; Quinolizines; Radioligand Assay; Receptors, Adrenergic, alpha-2; Recombinant Fusion Proteins; Rilmenidine; Saphenous Vein; Tritium | 1999 |